Affitech appoints cfo
Stig Jarle Pettersen was formerly a consultant to the Danish antibody medicines firm
Pettersen will be a member of the executive management of Affitech with managing director Martin Welschof and chief scientific officer Alexander Duncan.
Pettersen is a Norwegian state authorised public accountant with more than 20 years of experience at Hafslund Nycomed, Helicopter Services Group, Alpharma, Actavis and most recently as chief financial officer at Xellia Pharmaceuticals.
Pettersen worked as a consultant for Affitech in September 2009 and participated in the process of restructuring and refinancing the company. He now joins the company when, due to investment by TransNova in April, it is able to finance the further development of its two leading drug candidates in collaboration with NTSPlus of Russia.
Affitech expects to file a Clinical Trial Application in 2011 for its anti-VEGF antibody AT001/r84, whose main indication is for anti-angiogenesis treatment in several cancers.
You may also like
Research & Development
CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration
Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Research & Development
New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research
Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Research & Development
Chemify secures $1.6m Gates Foundation grant to accelerate digital chemistry for tuberculosis drug discovery
The follow-on funding supports Chemify and Lgenia in designing and synthesising new small-molecule candidates for high-priority TB targets using Chemify’s AI-driven digital chemistry platform
Research & Development
PLL Therapeutics opens New Zealand subsidiary to accelerate ALS clinical research in Asia-Pacific
The new entity will support Phase II ALS patient recruitment in New Zealand (where incidence rates exceed the global average) and expand PLL Therapeutics’ footprint in the Asia-Pacific neurodegenerative disease research landscape